A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a randomized, double‐blind, placebo‐controlled study to assess the safety and tolerability of GRF6021, a plasma derived product, administered by intravenous (IV) infusion to subjects with Parkinson's disease (PD) and cognitive impairment. The study duration for the subjects will be approximately 7 months.
Epistemonikos ID: f440010a8e888280c1c9a0a3b62342ae0f21c289
First added on: May 21, 2024